These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 33023856

  • 21. Immune status could determine efficacy of COVID-19 therapies.
    Cully M.
    Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
    [No Abstract] [Full Text] [Related]

  • 22. COVID-19 remedies.
    Nat Biomed Eng; 2020 Jun; 4(6):575-576. PubMed ID: 32533125
    [No Abstract] [Full Text] [Related]

  • 23. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
    Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C.
    Science; 2020 Aug 14; 369(6505):818-823. PubMed ID: 32616673
    [Abstract] [Full Text] [Related]

  • 24. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
    Stahel PF, Barnum SR.
    Front Immunol; 2020 Aug 14; 11():1661. PubMed ID: 32733489
    [No Abstract] [Full Text] [Related]

  • 25. COVID-19 and post-traumatic stress disorder: A vicious circle involving immunosuppression.
    Liang X, Zhu Y, Fang Y.
    CNS Neurosci Ther; 2020 Aug 14; 26(8):876-878. PubMed ID: 32678521
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The C5a/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia/reperfusion injury.
    Peng Q, Wu W, Wu KY, Cao B, Qiang C, Li K, Sacks SH, Zhou W.
    Kidney Int; 2019 Jul 14; 96(1):117-128. PubMed ID: 31029505
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Complement as a target in COVID-19?
    Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD.
    Nat Rev Immunol; 2020 Jun 14; 20(6):343-344. PubMed ID: 32327719
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
    Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters AH, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls PI, Griffiths CEM, Barker J, Irvine AD, Smith CH, Secure-AD and PsoProtect study groups.
    Br J Dermatol; 2020 Aug 14; 183(2):404-406. PubMed ID: 32348554
    [No Abstract] [Full Text] [Related]

  • 34. Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.
    Pandey S, Li XX, Srivastava A, Baidya M, Kumari P, Dwivedi H, Chaturvedi M, Ghosh E, Woodruff TM, Shukla AK.
    J Biol Chem; 2019 Jun 14; 294(24):9416-9429. PubMed ID: 31036565
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. COVID-19 management in light of the circadian clock.
    Ray S, Reddy AB.
    Nat Rev Mol Cell Biol; 2020 Sep 14; 21(9):494-495. PubMed ID: 32699357
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity.
    Gorman DM, Li XX, Lee JD, Fung JN, Cui CS, Lee HS, Rolfe BE, Woodruff TM, Clark RJ.
    J Med Chem; 2021 Nov 25; 64(22):16598-16608. PubMed ID: 34762432
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.